Daewon Pharm Co Ltd (Daewon) is a pharmaceutical company that manufactures and supplies pharmaceutical and medicinal products. The company offers a variety of products, including analgesics, respiratory treatments, antimicrobials, cardiovascular medications, antidiabetics, hepatic treatments, psychoneurotic medications, prostate treatments, multivitamins, endocrine treatments, over-the-counter (OTC) products, and functional foods. It also sells medical devices such as hearing aids. For the fiscal year ending in December 2023 (FY2023), Daewon reported revenues of USD 405.75 million, an increase of 10% over FY2022.

Generic Drug Development: DaeWon has a robust track record in developing high-quality generic drugs. The company employs advanced analytical techniques and manufacturing processes to ensure bioequivalence and efficacy. New Drug Development: DaeWon is expanding its R&D efforts to include the development of novel drug candidates, particularly in therapeutic areas where unmet medical needs exist. Formulation Development: The company has expertise in formulating various dosage forms to optimize drug delivery and improve patient compliance. Biosimilar Development: DaeWon is exploring the development of biosimilars, which are highly similar copies of original biologic products. Open Innovation: DaeWon actively collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate drug development and expand its product pipeline. Digital Health: Recognizing the growing importance of digital technologies in healthcare, DaeWon is investing in digital health solutions to improve patient care and optimize clinical trials.

Public

Pharma, CDMO, Bio